Trials / Completed
CompletedNCT04784442
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in Japanese patients with hypercholesterolemia treated for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 180mg of ETC-1002(bempedoic acid) | 180mg, tablet, once daily, for 12 weeks |
| DRUG | 120mg of ETC-1002(bempedoic acid) | 120mg, tablet, once daily, for 12 weeks |
| DRUG | 60mg of ETC-1002(bempedoic acid) | 60mg, tablet, once daily, for 12 weeks |
| DRUG | Placebo | placebo, tablet, once daily, for 12 weeks |
Timeline
- Start date
- 2021-03-24
- Primary completion
- 2022-04-18
- Completion
- 2022-05-17
- First posted
- 2021-03-05
- Last updated
- 2024-05-10
- Results posted
- 2024-03-04
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04784442. Inclusion in this directory is not an endorsement.